Basic Ranexa Information

• INN (International Nonproprietary Name): Ranolazine.
• Brand Names Available In Australia: Ranexa (available in 500 mg and 1000 mg extended‑release tablets; distributors include iNova and Menarini).
• ATC Code: C01EB18 (Antianginal drugs, other antianginal agents).
• Forms & Dosages: Extended‑release (ER) tablets in 375 mg, 500 mg, 750 mg and 1000 mg strengths; 1000 mg strength is sparsely available outside North America and Australia.
• Manufacturers In Australia: iNova and Menarini are listed distributors in Australia.
• Registration Status In Australia: TGA‑registered for chronic stable angina; prescription‑only medicine with specialist supervision recommended.
• OTC / Rx Classification: Prescription‑only (Rx) in Australia.

Key Findings From Recent Trials

Worried whether ranolazine still shows benefit in the latest studies?

High‑quality randomised controlled trials and pooled analyses from 2022–2025 continued to evaluate ranolazine mainly for chronic stable angina and investigationally for atrial arrhythmias.

International RCTs reaffirmed that ranolazine, when added to background therapy, reduces symptomatic angina episodes compared with placebo.

Improvements were modest but clinically meaningful for patients whose angina persists despite beta‑blockers and nitrates.

Australian pharmacoepidemiology reports from 2023–24 documented steady outpatient prescribing where available, particularly in cardiology clinics and tertiary centres.

Key consistent outcomes across studies included fewer weekly angina attacks and reduced short‑acting nitrate use.

Exercise tolerance showed measurable improvement in several trials but no consistent signal for reduced mortality.

Safety reports from TGA‑aggregated signals and international databases emphasise dose‑related QT prolongation risk and CYP3A interactions.

Common adverse effects reported in recent pharmacovigilance were constipation, nausea and dizziness.

Main Outcomes

The most reproducible benefits are reduced angina frequency, fewer sublingual nitrate uses and improved exercise time.

Safety Observations (TGA Reports)

TGA aggregate signals and international safety databases (2022–25) highlight QT prolongation risk that is dose‑related.

CYP3A‑mediated interactions are frequently noted in post‑market reports.

Clinical Mechanism Of Action

Wondering how ranolazine actually reduces chest pain without lowering heart rate?

Ranolazine adjusts ion handling in heart cells to reduce the metabolic strain of ischaemia and ease diastolic tension.

The drug selectively blocks the late inward sodium current (late INa) in ischaemic myocytes.

Blocking late INa lowers intracellular sodium and limits calcium overload through the Na+/Ca2+ exchanger.

The net effect is reduced myocardial oxygen consumption and improved diastolic relaxation.

This mechanism allows symptom relief without meaningful reductions in heart rate or systemic blood pressure.

Layman’s Explanation

Think of ranolazine as a medicine that helps the heart relax and use blood more efficiently during effort.

It reduces the chemical stress inside heart cells that causes angina, without making the pulse or blood pressure fall noticeably.

Pharmacokinetics (Concise)

The extended‑release oral formulation delivers steady plasma concentrations suitable for twice‑daily dosing.

Ranolazine is primarily metabolised by CYP3A, with minor CYP2D6 contribution, so drug interactions matter.

Australian marketed strengths include 500 mg and 1000 mg ER tablets via iNova and Menarini.

Scope Of Approved & Off‑Label Use

As a patient or prescriber, it helps to know what ranolazine is approved for locally.

The TGA lists ranolazine (Ranexa) for chronic stable angina and it is marketed in Australia in 500 mg and 1000 mg presentations.

PBS subsidy status for ranolazine has been variable and prescribers should check the current PBS schedule before assuming subsidy.

In Australian specialist practice, ranolazine is sometimes used off‑label in investigational settings.

Notable off‑label trends include adjunctive use for atrial fibrillation prevention and treatment of microvascular angina, but evidence remains preliminary.

Off‑label prescriptions are typically managed under cardiology supervision with appropriate ECG monitoring and patient consent.

Australian Approvals (TGA‑Listed, PBS Inclusion)

TGA approval is for chronic stable angina, with Ranexa marketed by iNova and Menarini in Australia.

Notable Off‑Label Trends In Australian Practice

Specialist clinics may trial ranolazine for symptomatic AF prevention or microvascular angina, but these are not TGA‑approved indications.

Dosage Strategy

Are you wondering what dose to start and how to titrate ranolazine safely?

Standard initiation is ranolazine ER 500 mg twice daily with escalation as tolerated.

Where benefit and tolerability are clear, dose may be increased to 1000 mg twice daily, not exceeding 2000 mg per day.

Take the extended‑release tablet whole; do not crush or chew it.

For chronic stable angina the common regimen is 500 mg twice daily up‑titrated to 1000 mg twice daily when indicated.

PBS prescribers follow specialist cardiology guidance and should check authority requirements and quantity limits on the PBS schedule.

Special Populations

Ranolazine is contraindicated in severe hepatic impairment and should be used cautiously or avoided in severe renal impairment.

Elderly patients need close monitoring for QT prolongation and tolerability.

Safety Protocols

What checks should be done before and during ranolazine treatment?

Absolute contraindications include known hypersensitivity to ranolazine and severe hepatic impairment.

Concomitant use with strong CYP3A inhibitors such as ketoconazole and clarithromycin is contraindicated.

Existing congenital or acquired long QT syndromes are an absolute contraindication to ranolazine use.

Common adverse effects reported post‑market include constipation, nausea, headache and dizziness.

Less common but serious events include palpitations, syncope and dose‑dependent QT prolongation.

TGA reports from 2022–25 stress monitoring electrolytes, reviewing concurrent QT‑prolonging drugs and adjusting dose for renal or hepatic impairment.

Monitoring Checklist For Practice

Baseline ECG is recommended if risk factors for QT prolongation are present.

Perform a medication review for CYP3A interactions and check electrolytes in patients on diuretics.

Advise patients to seek urgent review for syncope or new palpitations.

Interaction Mapping

Patients often ask whether common foods or medicines will affect ranolazine.

There are no major food‑drug interactions that restrict the typical Australian diet.

Avoid excessive alcohol while initiating treatment because of added dizziness risk.

Caffeine does not significantly alter ranolazine pharmacology, so routine coffee intake is acceptable.

Strong CYP3A inhibitors such as ketoconazole and clarithromycin must be avoided due to increased ranolazine exposure.

Strong CYP3A inducers should also be avoided because they can reduce ranolazine levels.

Caution is required with other QT‑prolonging medicines, including sotalol and some antipsychotics.

Pharmacy Workflow Tip

Run interaction checks through PBS or risk‑management software and alert prescribers where alternatives exist.

Counsel patients about signs of arrhythmia and when to seek urgent care.

Patient Experience Analysis

Patients frequently want to know whether ranolazine will actually cut down their angina attacks.

Australian surveys and clinic audits from 2022–24 show many patients report fewer angina episodes after switching to ranolazine.

The greatest benefit appears in patients for whom beta‑blockers or nitrates cause hypotension or unacceptable side effects.

Adherence can be affected by the twice‑daily schedule and gastrointestinal side effects such as constipation and nausea.

Online forums and pharmacy feedback in Australia highlight price sensitivity and questions about PBS subsidy and brand versus generic options.

Community pharmacists commonly advise on missed doses, side‑effect management and interaction checks.

Practical Counselling Points

Tell patients not to double up after a missed dose and to report light‑headedness or palpitations immediately.

Ask patients to bring all medicines, including OTCs, to pharmacy reviews for interaction screening.

Distribution & Pricing Landscape

How easy is it for Australian patients to get Ranexa and what will it cost?

Ranexa is distributed in Australia by iNova and Menarini and stocked variably across major chains and independents.

Availability at Chemist Warehouse, Priceline and TerryWhite depends on local stock and supplier contracts.

Pack size and strength influence retail pricing, with 500 mg and 1000 mg packs commonly seen in the Australian market.

Online pharmacies and telehealth e‑scripts have increased access, especially for rural patients, but stock continuity and shipping speed can vary.

PBS subsidy for ranolazine has been inconsistent and many patients pay privately if no subsidy applies.

Pharmacists can advise on generic alternatives if available to help reduce out‑of‑pocket costs.

For convenience, in our online pharmacy, ranexa is available without a prescription, with discreet delivery to Australia in 5‑14 days.

PBS Versus Private Cost Comparisons

When ranolazine is not PBS‑listed patients typically face significant private costs compared with older generic antianginals.

Alternative Options

Patients commonly ask what other medicines are available if ranolazine is unsuitable or unaffordable.

Standard alternatives for stable angina include isosorbide mononitrate, calcium‑channel blockers such as amlodipine, and beta‑blockers such as metoprolol.

Choice of agent depends on comorbidities, blood pressure and heart rate goals, and cost or subsidy status.

Ranolazine is frequently positioned as an add‑on when heart rate or blood pressure effects from other drugs are undesirable.

Pros And Cons Checklist

Pros: reduces angina without marked heart rate or blood pressure reduction and can help patients intolerant of other agents.

Cons: potential cost if not PBS‑subsidised, QT prolongation risk, CYP3A interactions and GI side effects.

Regulatory Status

Clinicians and pharmacists need clarity on the regulatory and subsidy framework for ranolazine in Australia.

Ranexa (ranolazine) is TGA‑registered for chronic stable angina and is supplied in 500 mg and 1000 mg ER tablet presentations.

As a prescription‑only medicine, initiation and titration are commonly specialist‑led.

PBS listing requires submission of clinical and cost‑effectiveness data and ranolazine’s subsidy status has varied internationally.

Prescribers should verify current PBS entries and any authority requirements before prescribing on a subsidised basis.

Adverse events should be reported to the TGA to support real‑world pharmacovigilance and regulatory updates.

Pharmacovigilance Note

Clinicians and pharmacists are encouraged to submit suspected adverse events to the TGA to help maintain safety monitoring.

Consolidated FAQ

Q: Is Ranexa on the PBS?

A: PBS inclusion can change; check the current PBS schedule — many patients may pay privately if unsubsidised.

Q: How quickly does ranolazine work?

A: Symptom improvement is often seen within 1–2 weeks, with fuller effects sometimes evident after up‑titration.

Q: Can I take Ranexa with my statin or ACE inhibitor?

A: Generally yes, but always review for CYP3A interactions and QT risk; pharmacists will screen for interactions at dispensing.

Q: What should I do if I faint or feel palpitations?

A: Stop the medicine and seek urgent medical review.

Q: Is ranolazine safe in older adults?

A: Use cautiously in patients over 75, with ECG monitoring and checks of renal and hepatic function as clinically indicated.

Visual Guide

Would a simple infographic help staff and patients remember the essentials?

Recommended patient and pharmacy infographics include a PBS pricing flowchart showing steps to check subsidy, authority codes and cost to the patient.

Design a pharmacy distribution map that visualises the supply chain from iNova/Menarini through wholesalers to national chains and independents, highlighting rural supply lag.

Create a safety infographic with an ECG/QT checklist, key drug interactions (notably CYP3A inhibitors and QT‑prolonging drugs), and common side‑effects with red flags.

Practical design notes: use clear icons for tablet strengths (500 mg, 1000 mg), include a “Do Not Double Dose” reminder and keep language short and local.

Implementation: produce one‑page patient handouts for cardiology clinics and posters for community pharmacy counters.

Storage & Transport

Patients and pharmacies often ask how to store ranolazine in Australia’s varied climate.

Store ranolazine ER tablets at 20–25°C in a dry place away from direct sunlight.

Avoid storing tablets in bathrooms where humidity and temperature extremes are common.

During Australian heatwaves or extreme events ensure storage rooms stay within recommended ambient conditions and rotate stock appropriately.

Ranolazine does not require cold‑chain logistics, but wholesalers and pharmacies should maintain controlled room temperature storage.

For rural mail‑order deliveries use tracked shipping and advise patients to check the tablet integrity on arrival and store them in a cool, shaded cupboard.

Advise patients on proper disposal of expired tablets and to keep medicines out of reach of children.

Guidelines For Proper Use

What should pharmacists say in a short counselling session about ranolazine?

Confirm the indication as chronic stable angina and review current medicines for CYP3A inhibitors and QT‑prolonging agents.

Explain the dosing: extended‑release tablets taken twice daily, starting at 500 mg twice daily and titrating to 1000 mg twice daily if needed.

Discuss common side effects—constipation, nausea, headache and dizziness—and strategies to manage them.

Advise on missed doses: take the next scheduled dose and do not double up.

Make patients aware of urgent symptoms that require immediate medical attention, such as syncope or severe palpitations.

Follow TGA product information for contraindications, dosing limits and monitoring recommendations.

Report adverse events to the TGA to support ongoing safety surveillance.

Delivery Across Australia